Tiny GLP-1 Starter Doses Still Trim Weight, Study Finds

A Reuters-reported study found that staying on the lowest starter doses of Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide still yields weight loss over a year, but far less than full-dose regimens (about 5.5% vs 20.2% for tirzepatide and 2.2% vs 13.7% for semaglutide); the low-dose groups also experienced more constipation and muscle cramps, though less nausea. The findings could broaden access to GLP-1 obesity drugs while raising questions about revenue per patient as the market nears an estimated $100 billion annually by 2030 and competition intensifies between Lilly and Novo.